Business · 13/11/2015Updated: 10/17/2026 · 1 min read
FDA Releases Guidance on Biomarker Qualification for Invasive Aspergillosis Treatment Studies
Summary
The US Food and Drug Administration (FDA) has published a guidance document outlining the use of Galactomannan as a biomarker for diagnosing Invasive Aspergillosis in clinical trials, allowing drug developers to streamline the enrollment process for patients with probable IA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →